NO324934B1 - Pyrrolo[2,3-d]pyramidinforbindelser som immunosuppresive midler - Google Patents
Pyrrolo[2,3-d]pyramidinforbindelser som immunosuppresive midler Download PDFInfo
- Publication number
- NO324934B1 NO324934B1 NO20026030A NO20026030A NO324934B1 NO 324934 B1 NO324934 B1 NO 324934B1 NO 20026030 A NO20026030 A NO 20026030A NO 20026030 A NO20026030 A NO 20026030A NO 324934 B1 NO324934 B1 NO 324934B1
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- alkyl
- amino
- pyrrolo
- pyrimidin
- Prior art date
Links
- 239000003018 immunosuppressive agent Substances 0.000 title description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 229960003444 immunosuppressant agent Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 135
- 150000001875 compounds Chemical class 0.000 claims description 122
- -1 hydroxy, amino Chemical group 0.000 claims description 86
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 24
- 108010019421 Janus Kinase 3 Proteins 0.000 claims description 24
- 102000006500 Janus Kinase 3 Human genes 0.000 claims description 24
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
- 125000004442 acylamino group Chemical group 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- JHQOCEWOJAFCTJ-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylic acid Chemical compound CC1CCN(C(O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 JHQOCEWOJAFCTJ-UHFFFAOYSA-N 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 7
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 102000001253 Protein Kinase Human genes 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 108060006633 protein kinase Proteins 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000024799 Thyroid disease Diseases 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- 238000002689 xenotransplantation Methods 0.000 claims description 6
- RDGVREXPTVNIOZ-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(O)C1 RDGVREXPTVNIOZ-UHFFFAOYSA-N 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KNRLJPBXCVZFKC-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(tetrazol-1-yl)ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=NN=N1 KNRLJPBXCVZFKC-UHFFFAOYSA-N 0.000 claims description 4
- YXPJSLNLGWWFQK-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzenesulfonamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(S(N)(=O)=O)C=C1 YXPJSLNLGWWFQK-UHFFFAOYSA-N 0.000 claims description 4
- BXLOTZYFEBJGFO-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC=1C=CON=1 BXLOTZYFEBJGFO-UHFFFAOYSA-N 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 4
- 125000005157 alkyl carboxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- WCEMRCSQVJUUEL-UHFFFAOYSA-N 2-cyclopropyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CC1 WCEMRCSQVJUUEL-UHFFFAOYSA-N 0.000 claims description 3
- XLWYJSMYNALODL-UHFFFAOYSA-N 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclopentan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(=O)C1 XLWYJSMYNALODL-UHFFFAOYSA-N 0.000 claims description 3
- TXZVMZALSHPMNV-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC=CS1 TXZVMZALSHPMNV-UHFFFAOYSA-N 0.000 claims description 3
- XZXYNRDSRVDEFY-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(3-methyl-1,2-thiazol-5-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC(C)=NS1 XZXYNRDSRVDEFY-UHFFFAOYSA-N 0.000 claims description 3
- JNDULUJHHAKHFI-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-methylsulfonylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 JNDULUJHHAKHFI-UHFFFAOYSA-N 0.000 claims description 3
- BAMSJXFWGUSAPN-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-nitrophenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 BAMSJXFWGUSAPN-UHFFFAOYSA-N 0.000 claims description 3
- MNZUYWZVJCMTLM-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-sulfamoylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(N)(=O)=O)C=C1 MNZUYWZVJCMTLM-UHFFFAOYSA-N 0.000 claims description 3
- KSZRXZRZFBENAS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[4-(methylsulfamoyl)phenyl]piperidine-1-carboxamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 KSZRXZRZFBENAS-UHFFFAOYSA-N 0.000 claims description 3
- HIOUMGNWXIKDEL-UHFFFAOYSA-N 4-methyl-n-(3-methyl-1,2-oxazol-4-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CON=C1C HIOUMGNWXIKDEL-UHFFFAOYSA-N 0.000 claims description 3
- NHFAFANWNRBBTO-UHFFFAOYSA-N 5-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]-1,3-thiazolidine-2,4-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1SC(=O)NC1=O NHFAFANWNRBBTO-UHFFFAOYSA-N 0.000 claims description 3
- IGNOXKOLEZVMMV-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(oxolan-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCOC1 IGNOXKOLEZVMMV-UHFFFAOYSA-N 0.000 claims description 3
- IKJVHXOXTUJMHW-UHFFFAOYSA-N cyclopentyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCC1 IKJVHXOXTUJMHW-UHFFFAOYSA-N 0.000 claims description 3
- CXQKRABZFZHQCW-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]furan-2-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CO1 CXQKRABZFZHQCW-UHFFFAOYSA-N 0.000 claims description 3
- WYAWBXYGRGZLTM-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-nitropyridin-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C([N+]([O-])=O)C=N1 WYAWBXYGRGZLTM-UHFFFAOYSA-N 0.000 claims description 3
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 2
- HJWUCTNLSFICSW-UHFFFAOYSA-N 2-[2-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]-1,3-thiazol-4-yl]acetic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC(CC(O)=O)=CS1 HJWUCTNLSFICSW-UHFFFAOYSA-N 0.000 claims description 2
- JTRGLKTYLIFFTR-UHFFFAOYSA-N 2-[4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]phenyl]acetic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(CC(O)=O)C=C1 JTRGLKTYLIFFTR-UHFFFAOYSA-N 0.000 claims description 2
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 claims description 2
- IFOXWHQFTSCNQB-UHFFFAOYSA-N 5-aminopyridine-2-carbonitrile Chemical compound NC1=CC=C(C#N)N=C1 IFOXWHQFTSCNQB-UHFFFAOYSA-N 0.000 claims description 2
- BIZBPVFLUUDEQH-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,3-thiazolidin-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCSC1 BIZBPVFLUUDEQH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 2
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 claims description 2
- YDALXWLQBQYZST-UHFFFAOYSA-N n-benzyl-n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N(C)CC1=CC=CC=C1 YDALXWLQBQYZST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- OUQMXTJYCAJLGO-UHFFFAOYSA-N 4-methyl-1,3-thiazol-2-amine Chemical compound CC1=CSC(N)=N1 OUQMXTJYCAJLGO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000002585 base Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 10
- 108010036949 Cyclosporine Proteins 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000004404 heteroalkyl group Chemical group 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- KEFMRZKKLKQKBB-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(6-methylsulfonylpyridin-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(C)(=O)=O)N=C1 KEFMRZKKLKQKBB-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 206010005089 Blast cell proliferation Diseases 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229940077388 benzenesulfonate Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N gamma-methylpyridine Natural products CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- UMWNXPTXDOVDFE-UHFFFAOYSA-N n-(1-benzyl-4-methylpiperidin-3-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=C1 UMWNXPTXDOVDFE-UHFFFAOYSA-N 0.000 description 3
- MKWSPUVYRGWYGY-UHFFFAOYSA-N n-[1-[(2-fluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=C1F MKWSPUVYRGWYGY-UHFFFAOYSA-N 0.000 description 3
- AXWBJJJQRJBTMI-UHFFFAOYSA-N n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CNC1=NC=NC2=C1C=CN2 AXWBJJJQRJBTMI-UHFFFAOYSA-N 0.000 description 3
- 229940063121 neoral Drugs 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- MMXJPJIKZFXULY-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1C#N MMXJPJIKZFXULY-UHFFFAOYSA-N 0.000 description 2
- MXXGGSPJLJXFSH-UHFFFAOYSA-N 2-imidazol-1-yl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=CN=C1 MXXGGSPJLJXFSH-UHFFFAOYSA-N 0.000 description 2
- KXZOTFGMNBPYTP-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzenesulfonyl fluoride Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(S(F)(=O)=O)C=C1 KXZOTFGMNBPYTP-UHFFFAOYSA-N 0.000 description 2
- XMAVNULAQUBQMQ-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C(O)=O)C=C1 XMAVNULAQUBQMQ-UHFFFAOYSA-N 0.000 description 2
- BKPKARLNQYNFRC-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylbenzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(C#N)C=C1 BKPKARLNQYNFRC-UHFFFAOYSA-N 0.000 description 2
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 2
- WQXRYEVRJRVDSK-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-methyl-1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC(C)=CS1 WQXRYEVRJRVDSK-UHFFFAOYSA-N 0.000 description 2
- LSGKKCWYBMNKRE-UHFFFAOYSA-N 6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridine-3-carbonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(C#N)C=N1 LSGKKCWYBMNKRE-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 150000001503 aryl iodides Chemical class 0.000 description 2
- 229940092117 atgam Drugs 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 229940107810 cellcept Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 229940073062 imuran Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229940014456 mycophenolate Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- VUAQEMYSGWNUMD-UHFFFAOYSA-N n-(2-cyanoethyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)NCCC#N)CC1N(C)C1=NC=NC2=C1C=CN2 VUAQEMYSGWNUMD-UHFFFAOYSA-N 0.000 description 2
- BGYQOFXRCCLHGH-UHFFFAOYSA-N n-[1-(2,4-difluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(F)C=C1F BGYQOFXRCCLHGH-UHFFFAOYSA-N 0.000 description 2
- CAHBCGJMNWWIHK-UHFFFAOYSA-N n-[1-(2,6-difluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=C(F)C=CC=C1F CAHBCGJMNWWIHK-UHFFFAOYSA-N 0.000 description 2
- MDWUMNUEIRPBGS-UHFFFAOYSA-N n-[1-(3,5-dichlorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 MDWUMNUEIRPBGS-UHFFFAOYSA-N 0.000 description 2
- KREZOGIZJJUJJZ-UHFFFAOYSA-N n-[1-(4-chlorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(Cl)C=C1 KREZOGIZJJUJJZ-UHFFFAOYSA-N 0.000 description 2
- FPRHYPXOQJQGQC-UHFFFAOYSA-N n-[1-(4-fluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(F)C=C1 FPRHYPXOQJQGQC-UHFFFAOYSA-N 0.000 description 2
- GLURSCMXAMMXQN-UHFFFAOYSA-N n-[1-(4-methoxyphenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 GLURSCMXAMMXQN-UHFFFAOYSA-N 0.000 description 2
- MFTWMFCKCRVSPQ-UHFFFAOYSA-N n-[1-(6-chloropyridin-3-yl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=C(Cl)N=C1 MFTWMFCKCRVSPQ-UHFFFAOYSA-N 0.000 description 2
- HLLYJLHURBDKCW-UHFFFAOYSA-N n-[1-[(3,5-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC(F)=CC(F)=C1 HLLYJLHURBDKCW-UHFFFAOYSA-N 0.000 description 2
- FUUJGALXOPJPPY-UHFFFAOYSA-N n-[1-[(3-chlorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(Cl)=C1 FUUJGALXOPJPPY-UHFFFAOYSA-N 0.000 description 2
- BBBOVXVBUYZWSD-UHFFFAOYSA-N n-[1-[3,5-bis(trifluoromethyl)phenyl]sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BBBOVXVBUYZWSD-UHFFFAOYSA-N 0.000 description 2
- XRIARWQZLGCQDM-UHFFFAOYSA-N n-methyl-n-(4-methylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CCNCC1N(C)C1=NC=NC2=C1C=CN2 XRIARWQZLGCQDM-UHFFFAOYSA-N 0.000 description 2
- GCEUCNYSHSTDDL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(1-phenylethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1CC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)CN1C(C)C1=CC=CC=C1 GCEUCNYSHSTDDL-UHFFFAOYSA-N 0.000 description 2
- YFDJCUNWPCDTMB-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[2-(trifluoromethyl)phenyl]sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1C(F)(F)F YFDJCUNWPCDTMB-UHFFFAOYSA-N 0.000 description 2
- KBNNITHCTOEGAP-UHFFFAOYSA-N n-tert-butyl-4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzenesulfonamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(S(=O)(=O)NC(C)(C)C)C=C1 KBNNITHCTOEGAP-UHFFFAOYSA-N 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 102200031660 rs730880032 Human genes 0.000 description 2
- 229940063122 sandimmune Drugs 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000003011 styrenyl group Chemical class [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- MEAVBNFGUHYRTG-UHFFFAOYSA-N (1,5-dimethylpyrazol-3-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=C(C)N(C)N=1 MEAVBNFGUHYRTG-UHFFFAOYSA-N 0.000 description 1
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- IQTLZOZLURQFLT-UHFFFAOYSA-N (3,4-dihydroxypyrrolidin-1-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CC(O)C(O)C1 IQTLZOZLURQFLT-UHFFFAOYSA-N 0.000 description 1
- YQFCATXTMSPGIX-UHFFFAOYSA-N (3-hydroxycyclopentyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(O)C1 YQFCATXTMSPGIX-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- GHCBTAVVWSPDJJ-UHFFFAOYSA-N (4-fluorophenyl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=C(F)C=C1 GHCBTAVVWSPDJJ-UHFFFAOYSA-N 0.000 description 1
- FOQWAMSIDZJEFW-UHFFFAOYSA-N (5,7-dichloro-1h-indol-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound ClC1=CC(Cl)=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 FOQWAMSIDZJEFW-UHFFFAOYSA-N 0.000 description 1
- XMXLKEXVFYCIBY-UHFFFAOYSA-N (5-chloro-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound ClC1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 XMXLKEXVFYCIBY-UHFFFAOYSA-N 0.000 description 1
- IYAFKKGFYHLLJK-UHFFFAOYSA-N (5-chloro-2,3-dihydro-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C2=CC(Cl)=CC=C2OC1C(=O)N1CCC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)C1 IYAFKKGFYHLLJK-UHFFFAOYSA-N 0.000 description 1
- QPWBKRGHRNNUSM-UHFFFAOYSA-N (5-fluoro-1h-indol-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound FC1=CC=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 QPWBKRGHRNNUSM-UHFFFAOYSA-N 0.000 description 1
- FFVIFWOAGYOEOW-UHFFFAOYSA-N (5-methoxy-3-methyl-1-benzofuran-2-yl)-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound CC=1C2=CC(OC)=CC=C2OC=1C(=O)N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 FFVIFWOAGYOEOW-UHFFFAOYSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- YCWQXMWZZNXJNC-UHFFFAOYSA-N 1-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1-benzofuran-5-yl]ethanone Chemical compound CC(=O)C1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 YCWQXMWZZNXJNC-UHFFFAOYSA-N 0.000 description 1
- XKIJFZMZBNZZGJ-UHFFFAOYSA-N 1-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCN1C(C)=O XKIJFZMZBNZZGJ-UHFFFAOYSA-N 0.000 description 1
- NFEWCNUVUHEPPS-UHFFFAOYSA-N 1-[3-methyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1h-indol-5-yl]ethanone Chemical compound N1C2=CC=C(C(C)=O)C=C2C(C)=C1C(=O)N1CCC(C)C(N(C)C=2C=3C=CNC=3N=CN=2)C1 NFEWCNUVUHEPPS-UHFFFAOYSA-N 0.000 description 1
- BFIJFTSOTVEXRP-UHFFFAOYSA-N 1-[4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCN(C(C)=O)CC1 BFIJFTSOTVEXRP-UHFFFAOYSA-N 0.000 description 1
- BXZWMPROQVAXHA-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(1,3-thiazolidin-3-ylsulfonyl)ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CS(=O)(=O)N1CCSC1 BXZWMPROQVAXHA-UHFFFAOYSA-N 0.000 description 1
- LFZCTGZBVFSCRQ-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-(4-methylphenyl)sulfonylethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CS(=O)(=O)C1=CC=C(C)C=C1 LFZCTGZBVFSCRQ-UHFFFAOYSA-N 0.000 description 1
- BUNOUGVLAYVGAE-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-methylsulfonylethanone Chemical compound CC1CCN(C(=O)CS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 BUNOUGVLAYVGAE-UHFFFAOYSA-N 0.000 description 1
- IVBUYSHJEHLIMK-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-morpholin-4-ylethane-1,2-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(=O)N1CCOCC1 IVBUYSHJEHLIMK-UHFFFAOYSA-N 0.000 description 1
- ZJFXSXNPKWZYTQ-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-phenoxyethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=CC=C1 ZJFXSXNPKWZYTQ-UHFFFAOYSA-N 0.000 description 1
- VUPATEHXQFNTIO-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-phenylethane-1,2-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(=O)C1=CC=CC=C1 VUPATEHXQFNTIO-UHFFFAOYSA-N 0.000 description 1
- BLXPTDGSXNVOKB-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-pyrazol-1-ylethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CN1C=CC=N1 BLXPTDGSXNVOKB-UHFFFAOYSA-N 0.000 description 1
- KBBNQXKKBALYNH-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-pyrrolidin-1-ylethane-1,2-dione Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(=O)N1CCCC1 KBBNQXKKBALYNH-UHFFFAOYSA-N 0.000 description 1
- YBLLNNSAWUBEKR-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-nitropropan-1-one Chemical compound CC1CCN(C(=O)CC[N+]([O-])=O)CC1N(C)C1=NC=NC2=C1C=CN2 YBLLNNSAWUBEKR-UHFFFAOYSA-N 0.000 description 1
- HEWZKTNWCFYMLF-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-2-one Chemical compound CC1CCN(CC(C)=O)CC1N(C)C1=NC=NC2=C1C=CN2 HEWZKTNWCFYMLF-UHFFFAOYSA-N 0.000 description 1
- RBROMUQSJAPIRW-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propane-1,2-dione Chemical compound CC1CCN(C(=O)C(C)=O)CC1N(C)C1=NC=NC2=C1C=CN2 RBROMUQSJAPIRW-UHFFFAOYSA-N 0.000 description 1
- XESQWPJSAAPPTR-UHFFFAOYSA-N 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]piperidine-4-carboxamide;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCC(C(N)=O)CC1 XESQWPJSAAPPTR-UHFFFAOYSA-N 0.000 description 1
- CKODHKNZMAPUTK-UHFFFAOYSA-N 1-benzyl-3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C(C1=O)CCN1CC1=CC=CC=C1 CKODHKNZMAPUTK-UHFFFAOYSA-N 0.000 description 1
- QRGQXVUZVXXWAG-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-ol Chemical compound C1C(O)C(C)CCN1CC1=CC=CC=C1 QRGQXVUZVXXWAG-UHFFFAOYSA-N 0.000 description 1
- BSBVJNUGGBQEPO-UHFFFAOYSA-N 1-benzyl-4-methylpiperidin-3-one Chemical compound C1C(=O)C(C)CCN1CC1=CC=CC=C1 BSBVJNUGGBQEPO-UHFFFAOYSA-N 0.000 description 1
- LJHMBIINLKLHSI-UHFFFAOYSA-M 1-benzyl-4-methylpyridin-1-ium;chloride Chemical compound [Cl-].C1=CC(C)=CC=[N+]1CC1=CC=CC=C1 LJHMBIINLKLHSI-UHFFFAOYSA-M 0.000 description 1
- ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- NIUHHXFPHLGXJZ-UHFFFAOYSA-N 1-methyl-4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CN(C)C(=O)C1 NIUHHXFPHLGXJZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HGMQPYNIMJVSEK-UHFFFAOYSA-N 1h-indol-2-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1=CC=C2NC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 HGMQPYNIMJVSEK-UHFFFAOYSA-N 0.000 description 1
- NWSXTGLTZBLHEF-UHFFFAOYSA-N 2,2-dimethyl-5-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]-1,3-dioxolan-4-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1OC(C)(C)OC1=O NWSXTGLTZBLHEF-UHFFFAOYSA-N 0.000 description 1
- KAKIPOYENBQNRH-UHFFFAOYSA-N 2,2-dimethylpropyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC1CCN(C(=O)OCC(C)(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 KAKIPOYENBQNRH-UHFFFAOYSA-N 0.000 description 1
- UQQDPUBXMGENLT-UHFFFAOYSA-N 2,4-difluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=C(F)C=C1F UQQDPUBXMGENLT-UHFFFAOYSA-N 0.000 description 1
- ORTAKGYHUCSVSP-UHFFFAOYSA-N 2-(4-fluorophenoxy)-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)COC1=CC=C(F)C=C1 ORTAKGYHUCSVSP-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JAUIMPSXWZMZOR-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-1,3-thiazol-5-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=C(N)S1 JAUIMPSXWZMZOR-UHFFFAOYSA-N 0.000 description 1
- ZPVYAUZMMIHOKY-UHFFFAOYSA-N 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetonitrile Chemical compound CC1CCN(CC#N)CC1N(C)C1=NC=NC2=C1C=CN2 ZPVYAUZMMIHOKY-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- YXBCFGXEZKKAJD-UHFFFAOYSA-N 2-cyclopentyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CCCC1 YXBCFGXEZKKAJD-UHFFFAOYSA-N 0.000 description 1
- XOFDIBJJAMYNPO-UHFFFAOYSA-N 2-cyclopropyl-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CC1CC1 XOFDIBJJAMYNPO-UHFFFAOYSA-N 0.000 description 1
- YSZSWVSNVMKHCJ-UHFFFAOYSA-N 2-fluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC=C1F YSZSWVSNVMKHCJ-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- CCOHWQFOFWCBMH-UHFFFAOYSA-N 2-hydroxy-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]ethanone Chemical compound CC1CCN(C(=O)CO)CC1N(C)C1=NC=NC2=C1C=CN2 CCOHWQFOFWCBMH-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- FXGUQUCAGSISKB-UHFFFAOYSA-N 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclohexan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCC(=O)C1 FXGUQUCAGSISKB-UHFFFAOYSA-N 0.000 description 1
- SZEYBHNUNGAPOQ-UHFFFAOYSA-N 3-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(C(O)=O)=C1 SZEYBHNUNGAPOQ-UHFFFAOYSA-N 0.000 description 1
- BJVVAQQNYISPQY-UHFFFAOYSA-N 3-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(C#N)=C1 BJVVAQQNYISPQY-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- UJRQBRQCRJAING-UHFFFAOYSA-N 3-chloro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC(Cl)=C1 UJRQBRQCRJAING-UHFFFAOYSA-N 0.000 description 1
- IMWCUOSIKDUHCK-UHFFFAOYSA-N 3-fluoro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC(F)=C1 IMWCUOSIKDUHCK-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- NUGKVVXANREPOX-UHFFFAOYSA-N 3-hydroxy-1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propan-1-one Chemical compound CC1CCN(C(=O)CCO)CC1N(C)C1=NC=NC2=C1C=CN2 NUGKVVXANREPOX-UHFFFAOYSA-N 0.000 description 1
- SJTDTLGBWDAFDJ-UHFFFAOYSA-N 3-methoxy-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound COC1=CC=CC(C(=O)NCCS(=O)(=O)N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 SJTDTLGBWDAFDJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- VKBWDXQRWNGFDC-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-1,3-thiazolidin-2-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CSC(=O)N1 VKBWDXQRWNGFDC-UHFFFAOYSA-N 0.000 description 1
- OBFJCFNQFDYZHU-UHFFFAOYSA-N 4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]cyclohexan-1-one Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC(=O)CC1 OBFJCFNQFDYZHU-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- DAGNWGTYQUFJPI-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzoic acid Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(C(O)=O)C=C1 DAGNWGTYQUFJPI-UHFFFAOYSA-N 0.000 description 1
- LNXDPZZVXXRBJV-UHFFFAOYSA-N 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methyl]benzonitrile Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=C(C#N)C=C1 LNXDPZZVXXRBJV-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- FTYXRILYMGQZIW-UHFFFAOYSA-N 4-chloro-5-nitro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C([N+](=O)[O-])=CNC2=N1 FTYXRILYMGQZIW-UHFFFAOYSA-N 0.000 description 1
- KAUCHHKKEDFVMC-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidin-5-amine Chemical compound N1C=NC(Cl)=C2C(N)=CN=C21 KAUCHHKKEDFVMC-UHFFFAOYSA-N 0.000 description 1
- GVLJTCVFFUOICL-UHFFFAOYSA-N 4-chloro-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=C(Cl)C=C1 GVLJTCVFFUOICL-UHFFFAOYSA-N 0.000 description 1
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 1
- YUOWAWBQTJNFPV-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(3-nitrophenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC([N+]([O-])=O)=C1 YUOWAWBQTJNFPV-UHFFFAOYSA-N 0.000 description 1
- CERCNXOIJVTNOI-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(4-phenylphenyl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC(C=C1)=CC=C1C1=CC=CC=C1 CERCNXOIJVTNOI-UHFFFAOYSA-N 0.000 description 1
- KAWWGHUFTZUUQJ-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(5-methyl-1,3,4-thiadiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NN=C(C)S1 KAWWGHUFTZUUQJ-UHFFFAOYSA-N 0.000 description 1
- VXPQMXUSNXGCGC-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(5-methyl-1,3-thiazol-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC=C(C)S1 VXPQMXUSNXGCGC-UHFFFAOYSA-N 0.000 description 1
- NLTMMUCSEQZBHA-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(5-nitropyridin-2-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C([N+]([O-])=O)C=N1 NLTMMUCSEQZBHA-UHFFFAOYSA-N 0.000 description 1
- NUMGKGIDXWEMIS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-(6-sulfamoylpyridin-3-yl)piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(N)(=O)=O)N=C1 NUMGKGIDXWEMIS-UHFFFAOYSA-N 0.000 description 1
- UIFWYZWDLKHIKJ-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[(4-methylsulfonylphenyl)methyl]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NCC1=CC=C(S(C)(=O)=O)C=C1 UIFWYZWDLKHIKJ-UHFFFAOYSA-N 0.000 description 1
- OQZBUDHKBPGIAY-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[4-(trifluoromethyl)phenyl]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(F)(F)F)C=C1 OQZBUDHKBPGIAY-UHFFFAOYSA-N 0.000 description 1
- MSPMHPJXWCDMMS-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-[5-(trifluoromethyl)pyridin-2-yl]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(F)(F)F)C=N1 MSPMHPJXWCDMMS-UHFFFAOYSA-N 0.000 description 1
- KXUXFNIWNUKJPR-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-pyridin-2-ylpiperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC=N1 KXUXFNIWNUKJPR-UHFFFAOYSA-N 0.000 description 1
- ULPBDCOXBBDOAA-UHFFFAOYSA-N 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-pyridin-3-ylpiperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CN=C1 ULPBDCOXBBDOAA-UHFFFAOYSA-N 0.000 description 1
- AXECWBLWTKUNKI-UHFFFAOYSA-N 4-methyl-n-(5-methyl-1,2-oxazol-3-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC=1C=C(C)ON=1 AXECWBLWTKUNKI-UHFFFAOYSA-N 0.000 description 1
- QOQLNRWVRJXYBY-UHFFFAOYSA-N 4-methyl-n-(6-methylpyridin-2-yl)-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC(C)=N1 QOQLNRWVRJXYBY-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- ZQDSVEIANVFLCB-UHFFFAOYSA-N 5-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]-n-propylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NCCC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 ZQDSVEIANVFLCB-UHFFFAOYSA-N 0.000 description 1
- GGXGVZJHUKEJHO-UHFFFAOYSA-N 5-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NO1 GGXGVZJHUKEJHO-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- GRHXJAWCOGOEEI-UHFFFAOYSA-N 6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridine-3-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(C(N)=O)C=N1 GRHXJAWCOGOEEI-UHFFFAOYSA-N 0.000 description 1
- UNQYAAAWKOOBFQ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-8-[4-chloro-3-(trifluoromethoxy)phenoxy]-1-(3-hydroxypropyl)-3-methylpurine-2,6-dione Chemical compound C=1C=C(Cl)C=CC=1CN1C=2C(=O)N(CCCO)C(=O)N(C)C=2N=C1OC1=CC=C(Cl)C(OC(F)(F)F)=C1 UNQYAAAWKOOBFQ-UHFFFAOYSA-N 0.000 description 1
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical group N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OVGSNVUVHVUHKX-UHFFFAOYSA-N Cl.C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 Chemical compound Cl.C1=CC(S(=O)(=O)NC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 OVGSNVUVHVUHKX-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000581002 Murex Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- FRNVQSITWLFBOC-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,2-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=NSC=1 FRNVQSITWLFBOC-UHFFFAOYSA-N 0.000 description 1
- LAXXEWWSKAEXQA-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(1,3-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CSC=N1 LAXXEWWSKAEXQA-UHFFFAOYSA-N 0.000 description 1
- RFXCMSIDTNASLB-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(2-methyl-1,3-thiazol-4-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CSC(C)=N1 RFXCMSIDTNASLB-UHFFFAOYSA-N 0.000 description 1
- OBNYTNLANQYAKG-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(4-methyl-1,2-thiazol-5-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1SN=CC=1C OBNYTNLANQYAKG-UHFFFAOYSA-N 0.000 description 1
- RUAQJYIYTBWUNM-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-methyl-1h-pyrazol-3-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=C(C)NN=1 RUAQJYIYTBWUNM-UHFFFAOYSA-N 0.000 description 1
- BUMQMCHZIVFESJ-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-methylthiophen-2-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=C(C)S1 BUMQMCHZIVFESJ-UHFFFAOYSA-N 0.000 description 1
- UHCGTWYKWVIEOO-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(5-nitro-1-benzofuran-2-yl)methanone Chemical compound [O-][N+](=O)C1=CC=C2OC(C(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=CC2=C1 UHCGTWYKWVIEOO-UHFFFAOYSA-N 0.000 description 1
- SOLFDRIEOMXKOP-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-(oxolan-2-yl)methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCO1 SOLFDRIEOMXKOP-UHFFFAOYSA-N 0.000 description 1
- QEOGTRNHPCFQLX-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-piperidin-1-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N1CCCCC1 QEOGTRNHPCFQLX-UHFFFAOYSA-N 0.000 description 1
- LRXSQANBZHZHCZ-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-pyridin-2-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1=CC=CC=N1 LRXSQANBZHZHCZ-UHFFFAOYSA-N 0.000 description 1
- CFQZFXWCFBDZIK-UHFFFAOYSA-N [4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-thiophen-3-ylmethanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=CSC=1 CFQZFXWCFBDZIK-UHFFFAOYSA-N 0.000 description 1
- GZEMWMLTGAYLBT-UHFFFAOYSA-N [6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyridin-3-yl]methanol Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=C(CO)C=N1 GZEMWMLTGAYLBT-UHFFFAOYSA-N 0.000 description 1
- NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- SXPLDGFSEXIUBZ-UHFFFAOYSA-N azetidin-3-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CNC1 SXPLDGFSEXIUBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- VEXPBNIZLGFIDN-UHFFFAOYSA-N benzyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)OCC1=CC=CC=C1 VEXPBNIZLGFIDN-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PTMBWDICPIENIA-UHFFFAOYSA-N cyclobutyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCC1 PTMBWDICPIENIA-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- SCIVYQMCQDJIGQ-UHFFFAOYSA-N cyclopropyl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CC1 SCIVYQMCQDJIGQ-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GAYDGVKMRJRIBA-UHFFFAOYSA-N dioxolan-4-one Chemical compound O=C1COOC1 GAYDGVKMRJRIBA-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- STPGXNKIIWAKOY-UHFFFAOYSA-N ethyl 2-[2-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(NC(=O)N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 STPGXNKIIWAKOY-UHFFFAOYSA-N 0.000 description 1
- KFJVOMUBTRMMJQ-UHFFFAOYSA-N ethyl 4-[[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 KFJVOMUBTRMMJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- JYEJANHTIHUXJA-UHFFFAOYSA-N furan-3-yl-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]methanone Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C=1C=COC=1 JYEJANHTIHUXJA-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000049912 human JAK3 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- GHXZPUGJZVBLGC-UHFFFAOYSA-N iodoethene Chemical compound IC=C GHXZPUGJZVBLGC-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- ZANBAWCCGAZGAI-UHFFFAOYSA-N methyl 1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1C(=O)N1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 ZANBAWCCGAZGAI-UHFFFAOYSA-N 0.000 description 1
- OFCJBGWMMGEZCC-UHFFFAOYSA-N methyl 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-1,3-benzoxazole-6-carboxylate Chemical compound O1C2=CC(C(=O)OC)=CC=C2N=C1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 OFCJBGWMMGEZCC-UHFFFAOYSA-N 0.000 description 1
- MBBWHWXFWMYUEZ-UHFFFAOYSA-N methyl 3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanoate Chemical compound C1N(C(=O)CC(=O)OC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 MBBWHWXFWMYUEZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PWNBFGLPPQHBOG-UHFFFAOYSA-N n',n'-dimethyl-n-[6-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]pyrimidin-4-yl]ethane-1,2-diamine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC(NCCN(C)C)=NC=N1 PWNBFGLPPQHBOG-UHFFFAOYSA-N 0.000 description 1
- WGHOFUHCMAYAKR-UHFFFAOYSA-N n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-n-phenylpiperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)N(C)C1=CC=CC=C1 WGHOFUHCMAYAKR-UHFFFAOYSA-N 0.000 description 1
- FJZHONHKCYKRQB-UHFFFAOYSA-N n,n-dimethyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetamide Chemical compound CC1CCN(CC(=O)N(C)C)CC1N(C)C1=NC=NC2=C1C=CN2 FJZHONHKCYKRQB-UHFFFAOYSA-N 0.000 description 1
- WTAVUCSHHBXNAU-UHFFFAOYSA-N n-(2,4-difluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C=C1F WTAVUCSHHBXNAU-UHFFFAOYSA-N 0.000 description 1
- MHJPHXRIIZFJRD-UHFFFAOYSA-N n-(2,5-dimethylpyrazol-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC(C)=NN1C MHJPHXRIIZFJRD-UHFFFAOYSA-N 0.000 description 1
- WCRSFPARSWZFGJ-UHFFFAOYSA-N n-(2-cyanoethyl)-n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)N(C)CCC#N)CC1N(C)C1=NC=NC2=C1C=CN2 WCRSFPARSWZFGJ-UHFFFAOYSA-N 0.000 description 1
- CSSVJWJGZOFBGB-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C(F)=C1 CSSVJWJGZOFBGB-UHFFFAOYSA-N 0.000 description 1
- KTVSFKVDVONQQP-UHFFFAOYSA-N n-(3-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=CC(C#N)=C1 KTVSFKVDVONQQP-UHFFFAOYSA-N 0.000 description 1
- LXKUADWXZVTYED-UHFFFAOYSA-N n-(3-methoxyphenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 LXKUADWXZVTYED-UHFFFAOYSA-N 0.000 description 1
- MXVHUWBDCJWJBY-UHFFFAOYSA-N n-(4,5-dimethyl-1,3-thiazol-2-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=NC(C)=C(C)S1 MXVHUWBDCJWJBY-UHFFFAOYSA-N 0.000 description 1
- UKRCCLOCZAYFDB-UHFFFAOYSA-N n-(4-carbamoylphenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C(N)=O)C=C1 UKRCCLOCZAYFDB-UHFFFAOYSA-N 0.000 description 1
- PJPPECSJTSUKLO-UHFFFAOYSA-N n-(4-chlorophenyl)-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]acetamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC(=O)NC1=CC=C(Cl)C=C1 PJPPECSJTSUKLO-UHFFFAOYSA-N 0.000 description 1
- HOMLLBRPTTUVDV-UHFFFAOYSA-N n-(4-chlorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)C=C1 HOMLLBRPTTUVDV-UHFFFAOYSA-N 0.000 description 1
- KUXDTNVHBXEUSG-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexane-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCC1C(=O)NC1=CC=C(C#N)C=C1 KUXDTNVHBXEUSG-UHFFFAOYSA-N 0.000 description 1
- VEMGCXQTHHJHSV-UHFFFAOYSA-N n-(4-cyanophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C#N)C=C1 VEMGCXQTHHJHSV-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- WEUCBDWSLVVWDC-UHFFFAOYSA-N n-(4-fluorophenyl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(F)C=C1 WEUCBDWSLVVWDC-UHFFFAOYSA-N 0.000 description 1
- WWYDCWWLOPCSKF-UHFFFAOYSA-N n-(5,6-dichloro-1,3-benzothiazol-2-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound ClC1=C(Cl)C=C2SC(NC(=O)N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 WWYDCWWLOPCSKF-UHFFFAOYSA-N 0.000 description 1
- OEYQMFLXKYNHHX-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)C=N1 OEYQMFLXKYNHHX-UHFFFAOYSA-N 0.000 description 1
- APGNKVVDKKJBSA-UHFFFAOYSA-N n-(5-cyclopropyl-2-methylpyrazol-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC(N(N=1)C)=CC=1C1CC1 APGNKVVDKKJBSA-UHFFFAOYSA-N 0.000 description 1
- VRYPRPWUASLBKW-UHFFFAOYSA-N n-(6-acetamidopyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(NC(C)=O)N=C1 VRYPRPWUASLBKW-UHFFFAOYSA-N 0.000 description 1
- DARQGOIBFWYTDR-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(Cl)N=C1 DARQGOIBFWYTDR-UHFFFAOYSA-N 0.000 description 1
- PJIDNSQIATYRAD-UHFFFAOYSA-N n-(6-cyanopyridin-3-yl)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(C#N)N=C1 PJIDNSQIATYRAD-UHFFFAOYSA-N 0.000 description 1
- WKRCPOAZAYSITM-UHFFFAOYSA-N n-(cyanomethyl)-n,4-dimethyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound CC1CCN(C(=O)N(C)CC#N)CC1N(C)C1=NC=NC2=C1C=CN2 WKRCPOAZAYSITM-UHFFFAOYSA-N 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- RZYWIDPSIUNGKK-UHFFFAOYSA-N n-[1-(1,3-benzothiazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=C2SC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 RZYWIDPSIUNGKK-UHFFFAOYSA-N 0.000 description 1
- NIBJZAILJOWIQQ-UHFFFAOYSA-N n-[1-(1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 NIBJZAILJOWIQQ-UHFFFAOYSA-N 0.000 description 1
- VADLXRPQOFCWQX-UHFFFAOYSA-N n-[1-(1h-imidazol-2-ylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CN1 VADLXRPQOFCWQX-UHFFFAOYSA-N 0.000 description 1
- JITFZYYWBKUOOK-UHFFFAOYSA-N n-[1-(2-chloropyrimidin-4-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=NC(Cl)=N1 JITFZYYWBKUOOK-UHFFFAOYSA-N 0.000 description 1
- UAONIQCOJSBENP-UHFFFAOYSA-N n-[1-(3-fluorophenyl)sulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC(F)=C1 UAONIQCOJSBENP-UHFFFAOYSA-N 0.000 description 1
- XVEOPYFRZSNYRS-UHFFFAOYSA-N n-[1-(4-chloropyrimidin-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=CC(Cl)=N1 XVEOPYFRZSNYRS-UHFFFAOYSA-N 0.000 description 1
- BZUPLPCFCWNQJZ-UHFFFAOYSA-N n-[1-(5,7-dichloro-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=CC(Cl)=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 BZUPLPCFCWNQJZ-UHFFFAOYSA-N 0.000 description 1
- SDTDZNFZCYBCMW-UHFFFAOYSA-N n-[1-(5-chloro-1,3-benzothiazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=CC=C2SC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 SDTDZNFZCYBCMW-UHFFFAOYSA-N 0.000 description 1
- HZQZOIOMQQURSQ-UHFFFAOYSA-N n-[1-(5-ethylsulfonyl-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C2=CC(S(=O)(=O)CC)=CC=C2OC=1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 HZQZOIOMQQURSQ-UHFFFAOYSA-N 0.000 description 1
- NKJRMXWUWIKAKK-UHFFFAOYSA-N n-[1-(6-chloropyrimidin-4-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC(Cl)=NC=N1 NKJRMXWUWIKAKK-UHFFFAOYSA-N 0.000 description 1
- KZLGBKRXQFQMGR-UHFFFAOYSA-N n-[1-(6-methoxy-1,3-benzoxazol-2-yl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound O1C2=CC(OC)=CC=C2N=C1N(C1)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 KZLGBKRXQFQMGR-UHFFFAOYSA-N 0.000 description 1
- XAIXADYENDVRSQ-UHFFFAOYSA-N n-[1-(benzenesulfonyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC=C1 XAIXADYENDVRSQ-UHFFFAOYSA-N 0.000 description 1
- AOTIOZSNQFPNJH-UHFFFAOYSA-N n-[1-(benzenesulfonylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CS(=O)(=O)C1=CC=CC=C1 AOTIOZSNQFPNJH-UHFFFAOYSA-N 0.000 description 1
- RNLIKTXBRLXGPY-UHFFFAOYSA-N n-[1-(furan-2-ylmethyl)-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CO1 RNLIKTXBRLXGPY-UHFFFAOYSA-N 0.000 description 1
- KUMDRRYTRPBDNI-UHFFFAOYSA-N n-[1-[(1-hydroxy-2h-pyridin-4-yl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CCN(O)C=C1 KUMDRRYTRPBDNI-UHFFFAOYSA-N 0.000 description 1
- AVRPPQPEZXXZIO-UHFFFAOYSA-N n-[1-[(2,3-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(F)=C1F AVRPPQPEZXXZIO-UHFFFAOYSA-N 0.000 description 1
- XWIXMEMJUUUXDV-UHFFFAOYSA-N n-[1-[(2,6-difluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=C(F)C=CC=C1F XWIXMEMJUUUXDV-UHFFFAOYSA-N 0.000 description 1
- DJNKXFFWPIEPST-UHFFFAOYSA-N n-[1-[(3-fluorophenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC(F)=C1 DJNKXFFWPIEPST-UHFFFAOYSA-N 0.000 description 1
- XENGQHJCGXVHPS-UHFFFAOYSA-N n-[1-[(3-methoxyphenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(CN2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 XENGQHJCGXVHPS-UHFFFAOYSA-N 0.000 description 1
- OHXSTMVQELSZED-UHFFFAOYSA-N n-[1-[(4-methoxyphenyl)methyl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CN1CC(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CC1 OHXSTMVQELSZED-UHFFFAOYSA-N 0.000 description 1
- LOLJQNSXOMKFMT-UHFFFAOYSA-N n-[1-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]ethylidene]hydroxylamine Chemical compound CC1CCC(C(C)=NO)CC1N(C)C1=NC=NC2=C1C=CN2 LOLJQNSXOMKFMT-UHFFFAOYSA-N 0.000 description 1
- IQKOFVVNSXCJSN-UHFFFAOYSA-N n-[1-[6-(benzylamino)pyrimidin-4-yl]-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=CN=1)=CC=1NCC1=CC=CC=C1 IQKOFVVNSXCJSN-UHFFFAOYSA-N 0.000 description 1
- VNRNTKQDEUHFNS-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]-1,2-oxazole-5-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=NO1 VNRNTKQDEUHFNS-UHFFFAOYSA-N 0.000 description 1
- AQHVRSUYNGNXOZ-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]benzamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1=CC=CC=C1 AQHVRSUYNGNXOZ-UHFFFAOYSA-N 0.000 description 1
- YPXYWAIYERNCLD-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclohexanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CCCCC1 YPXYWAIYERNCLD-UHFFFAOYSA-N 0.000 description 1
- JRFILNRCZMZHQZ-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclopentanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CCCC1 JRFILNRCZMZHQZ-UHFFFAOYSA-N 0.000 description 1
- VKODGQHCYLJNPG-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]methanesulfonamide Chemical compound CC1CCN(S(=O)(=O)CCNS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 VKODGQHCYLJNPG-UHFFFAOYSA-N 0.000 description 1
- BMDWQZXJMCYZQR-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]oxolane-2-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CCCO1 BMDWQZXJMCYZQR-UHFFFAOYSA-N 0.000 description 1
- IQWIPSPAKLTUJY-UHFFFAOYSA-N n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]oxolane-3-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCNC(=O)C1CCOC1 IQWIPSPAKLTUJY-UHFFFAOYSA-N 0.000 description 1
- BZECEBZZCGKPGV-UHFFFAOYSA-N n-[3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropyl]cyclohexanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)CCNC(=O)C1CCCCC1 BZECEBZZCGKPGV-UHFFFAOYSA-N 0.000 description 1
- BWODOSRHYYFYAL-UHFFFAOYSA-N n-[4-(acetylsulfamoyl)phenyl]-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)NC1=CC=C(S(=O)(=O)NC(C)=O)C=C1 BWODOSRHYYFYAL-UHFFFAOYSA-N 0.000 description 1
- UEMXCVXXCWBSQO-UHFFFAOYSA-N n-[4-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-4-oxobutyl]methanesulfonamide Chemical compound CC1CCN(C(=O)CCCNS(C)(=O)=O)CC1N(C)C1=NC=NC2=C1C=CN2 UEMXCVXXCWBSQO-UHFFFAOYSA-N 0.000 description 1
- NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
- JGDAYRXXBGXXGG-UHFFFAOYSA-N n-methyl-2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoacetamide Chemical compound C1N(C(=O)C(=O)NC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 JGDAYRXXBGXXGG-UHFFFAOYSA-N 0.000 description 1
- RBOKEUPEGKRTPI-UHFFFAOYSA-N n-methyl-3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]propanamide Chemical compound C1N(CCC(=O)NC)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 RBOKEUPEGKRTPI-UHFFFAOYSA-N 0.000 description 1
- BVTNPNHLLMJVAZ-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-pyridin-2-ylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=CC=CC=N1 BVTNPNHLLMJVAZ-UHFFFAOYSA-N 0.000 description 1
- MUFDJXPYGHSTCL-UHFFFAOYSA-N n-methyl-n-(4-methyl-1-pyrrolidin-1-ylsulfonylpiperidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)N1CCCC1 MUFDJXPYGHSTCL-UHFFFAOYSA-N 0.000 description 1
- MVCSSSGKQCMNFQ-UHFFFAOYSA-N n-methyl-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]cyclohexanecarboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCN(C)C(=O)C1CCCCC1 MVCSSSGKQCMNFQ-UHFFFAOYSA-N 0.000 description 1
- XDTBKAINQHKFRC-UHFFFAOYSA-N n-methyl-n-[2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]oxolane-3-carboxamide Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)CCN(C)C(=O)C1CCOC1 XDTBKAINQHKFRC-UHFFFAOYSA-N 0.000 description 1
- AHXCJQMWLAFGPB-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(1,3-thiazol-2-ylmethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CS1 AHXCJQMWLAFGPB-UHFFFAOYSA-N 0.000 description 1
- IQGBQQYFBCFKHW-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(2,2,2-trifluoroethylsulfonyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1CCN(S(=O)(=O)CC(F)(F)F)CC1N(C)C1=NC=NC2=C1C=CN2 IQGBQQYFBCFKHW-UHFFFAOYSA-N 0.000 description 1
- VJVUKGGLJWGDIL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(3-methylphenyl)sulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1S(=O)(=O)C1=CC=CC(C)=C1 VJVUKGGLJWGDIL-UHFFFAOYSA-N 0.000 description 1
- WTWUATJRKRYIEC-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(4-pyrrolidin-1-ylpyrimidin-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=1)=NC=CC=1N1CCCC1 WTWUATJRKRYIEC-UHFFFAOYSA-N 0.000 description 1
- OHYJNSIOYVRHEF-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-nitro-1,3-thiazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C1=NC=C([N+]([O-])=O)S1 OHYJNSIOYVRHEF-UHFFFAOYSA-N 0.000 description 1
- SRXRYNIPRVJWPC-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(5-pyrrolidin-1-ylsulfonylpyridin-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(N=C1)=CC=C1S(=O)(=O)N1CCCC1 SRXRYNIPRVJWPC-UHFFFAOYSA-N 0.000 description 1
- IGTBMXYYACQAJI-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(6-nitro-1,3-benzoxazol-2-yl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=C([N+]([O-])=O)C=C2OC(N3CCC(C(C3)N(C)C=3C=4C=CNC=4N=CN=3)C)=NC2=C1 IGTBMXYYACQAJI-UHFFFAOYSA-N 0.000 description 1
- WXYYHGAYLYQELZ-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-(pyridin-2-ylmethyl)piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=CC=CC=N1 WXYYHGAYLYQELZ-UHFFFAOYSA-N 0.000 description 1
- ZHXWETHAYBXKEL-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[(1-methylimidazol-2-yl)methyl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC1=NC=CN1C ZHXWETHAYBXKEL-UHFFFAOYSA-N 0.000 description 1
- CWIUUIXHTNTBDN-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[(4-piperidin-1-ylsulfonylphenyl)methyl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1CC(C=C1)=CC=C1S(=O)(=O)N1CCCCC1 CWIUUIXHTNTBDN-UHFFFAOYSA-N 0.000 description 1
- XHEHEYSNUXNFKG-UHFFFAOYSA-N n-methyl-n-[4-methyl-1-[6-(methylamino)pyrimidin-4-yl]piperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=NC(NC)=CC(N2CC(C(C)CC2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 XHEHEYSNUXNFKG-UHFFFAOYSA-N 0.000 description 1
- UICIJOHWFFTRLI-UHFFFAOYSA-N n-phenylpiperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)NC1=CC=CC=C1 UICIJOHWFFTRLI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- ZAHJXIZFAHUPFW-UHFFFAOYSA-N oxolan-3-yl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)OC1CCOC1 ZAHJXIZFAHUPFW-UHFFFAOYSA-N 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ZVBFIWUGPSGVEL-UHFFFAOYSA-N prop-2-ynyl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC1CCN(C(=O)OCC#C)CC1N(C)C1=NC=NC2=C1C=CN2 ZVBFIWUGPSGVEL-UHFFFAOYSA-N 0.000 description 1
- MAFFVYBHTVKZMC-UHFFFAOYSA-N propan-2-yl 4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)C)CCC(C)C1N(C)C1=NC=NC2=C1C=CN2 MAFFVYBHTVKZMC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BJVKTRODDXZYQJ-UHFFFAOYSA-N tert-butyl 2-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound C1C(N(C)C=2C=3C=CNC=3N=CN=2)C(C)CCN1C(=O)C1CCCN1C(=O)OC(C)(C)C BJVKTRODDXZYQJ-UHFFFAOYSA-N 0.000 description 1
- XHJLRKFGVYNHSA-UHFFFAOYSA-N tert-butyl n-[3-[4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carbonyl]-3-azabicyclo[3.1.0]hexan-6-yl]carbamate Chemical compound CC1CCN(C(=O)N2CC3C(C3NC(=O)OC(C)(C)C)C2)CC1N(C)C1=NC=NC2=C1C=CN2 XHJLRKFGVYNHSA-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21428700P | 2000-06-26 | 2000-06-26 | |
PCT/IB2001/000975 WO2002000661A1 (en) | 2000-06-26 | 2001-06-05 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20026030D0 NO20026030D0 (no) | 2002-12-16 |
NO20026030L NO20026030L (no) | 2002-12-16 |
NO324934B1 true NO324934B1 (no) | 2008-01-07 |
Family
ID=22798508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20026030A NO324934B1 (no) | 2000-06-26 | 2002-12-16 | Pyrrolo[2,3-d]pyramidinforbindelser som immunosuppresive midler |
Country Status (48)
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS50087B (sr) * | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
EP1147214B1 (en) | 1999-01-13 | 2011-01-05 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
PT1235830E (pt) | 1999-12-10 | 2004-04-30 | Pfizer Prod Inc | Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
EP1444204A4 (en) * | 2001-10-22 | 2009-11-04 | Univ New York State Res Found | INHIBITORS OF PROTEIN KINASES AND PROTEINS PHOSPHATASES, METHODS OF IDENTIFICATION AND METHODS OF USE THEREOF |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
EP1388541A1 (en) * | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
CA2507392A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
ES2383895T3 (es) | 2003-07-15 | 2012-06-27 | Dainippon Sumitomo Pharma Co., Ltd. | Nuevo derivado de heteroarilo |
EP1656372B1 (en) | 2003-07-30 | 2013-04-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
EP1689407A1 (en) * | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
WO2005097129A2 (en) * | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | 6-azaindole compound |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
US7358250B2 (en) | 2004-06-29 | 2008-04-15 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity |
EP1781287A4 (en) * | 2004-08-13 | 2008-02-27 | Genentech Inc | THIAZOLE-BASED COMPOUNDS HAVING ENZYMATIC INHIBITORY ACTIVITY USING ADENOSINE TRIPHOSPHATE (ATP) |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
WO2006101937A1 (en) | 2005-03-18 | 2006-09-28 | Janssen Pharmaceutica N.V. | Acylhydrazones as kinase modulators |
EP1891066B1 (en) | 2005-05-13 | 2010-12-22 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
SG137989A1 (en) | 2005-06-08 | 2008-01-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK pathway |
US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
ES2970354T3 (es) * | 2005-12-13 | 2024-05-28 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de Janus quinasas |
CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
WO2008029237A2 (en) * | 2006-09-05 | 2008-03-13 | Pfizer Products Inc. | Combination therapies for rheumatoid arthritis |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
JP5287253B2 (ja) | 2007-01-12 | 2013-09-11 | アステラス製薬株式会社 | 縮合ピリジン化合物 |
TR201903488T4 (tr) | 2007-06-13 | 2019-04-22 | Incyte Holdings Corp | Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı. |
CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR101494734B1 (ko) | 2007-10-11 | 2015-02-26 | 아스트라제네카 아베 | 단백질 키나제 b 억제제로서 피롤로[2,3-d]피리미딘 유도체 |
WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
RS55263B1 (sr) | 2008-03-11 | 2017-02-28 | Incyte Holdings Corp | Derivati azetidina i ciklobutana kao jak inhibitori |
NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
KR20110050654A (ko) * | 2008-08-01 | 2011-05-16 | 바이오크리스트 파마수티컬즈, 인코퍼레이티드 | Jak3 억제제로서의 피페리딘 유도체 |
BRPI0917459B1 (pt) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide |
US8385364B2 (en) * | 2008-09-24 | 2013-02-26 | Nec Laboratories America, Inc. | Distributed message-passing based resource allocation in wireless systems |
US8592415B2 (en) * | 2009-02-11 | 2013-11-26 | Reaction Biology Corp. | Selective kinase inhibitors |
SG173178A1 (en) | 2009-04-03 | 2011-09-29 | Hoffmann La Roche | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
CA2759026C (en) | 2009-04-20 | 2019-01-15 | Auspex Pharmaceuticals, Inc. | Piperidine inhibitors of janus kinase 3 |
KR101771401B1 (ko) | 2009-05-22 | 2017-08-25 | 인사이트 홀딩스 코포레이션 | 야누스 키나제 억제제로서 피라졸4일피롤로[2,3d]피리미딘 및 피롤3일피롤로[2,3d]피리미딘의 N(헤테로)아릴피롤리딘 유도체 |
TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為jak抑制劑之3-〔4-(7h-吡咯并〔2,3-d〕嘧啶-4-基)-1h-吡唑-1-基〕辛烷或庚腈 |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
EP3461824B1 (en) | 2009-09-04 | 2021-08-25 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
EA021478B1 (ru) | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
CA2776028C (en) * | 2009-10-15 | 2015-12-01 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
JP2013510166A (ja) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | キナーゼ調節のための化合物、方法およびその適用 |
JP5739446B2 (ja) * | 2009-12-18 | 2015-06-24 | ファイザー・インク | ピロロ[2,3−d]ピリミジン化合物 |
WO2011097087A1 (en) | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
CA2788659C (en) * | 2010-02-24 | 2015-05-05 | Pfizer Inc. | Veterinary compositions |
DK2545045T3 (en) | 2010-03-10 | 2016-01-25 | Incyte Holdings Corp | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
CN103002875B (zh) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Jak抑制剂的局部用制剂 |
WO2012022265A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
RS58455B1 (sr) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Jedinjenja i postupci za modulaciju kinaze, i indikacije za njih |
PT2675451E (pt) | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
JP6277121B2 (ja) | 2011-03-22 | 2018-02-07 | アドヴィナス・セラピューティックス・リミテッド | 置換された縮合三環式化合物、その組成物および医学的応用 |
MY169449A (en) | 2011-04-01 | 2019-04-11 | Astrazeneca Ab | Therapeutic treatment |
MX344479B (es) | 2011-06-20 | 2016-12-16 | Incyte Holdings Corp | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak). |
CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
DK2785349T4 (da) | 2011-11-30 | 2023-01-09 | Astrazeneca Ab | Kombinationsbehandling af cancer |
CA2857977C (en) | 2011-12-21 | 2020-10-20 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof |
CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
JP2015529242A (ja) | 2012-09-21 | 2015-10-05 | アドヴィヌス セラピューティクス リミテッドAdvinus Therapeutics Limited | 置換された縮合三環式化合物、組成物およびその医薬用途 |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
KR20210037012A (ko) | 2012-11-15 | 2021-04-05 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
WO2014097150A1 (en) | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Process for the preparation of tofacitinib and intermediates thereof |
MY177476A (en) | 2013-02-22 | 2020-09-16 | Pfizer | Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak) |
CA2903418C (en) | 2013-03-06 | 2021-03-23 | Incyte Corporation | Processes and intermediates for making a jak inhibitor |
CN107417691B (zh) | 2013-03-15 | 2020-06-26 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
JP6337083B2 (ja) | 2013-03-15 | 2018-06-06 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | Rbポジティブ異常細胞増殖に対するhspc温存治療 |
AU2014277506B2 (en) * | 2013-06-07 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor |
BR122020001831A8 (pt) | 2013-08-07 | 2023-01-24 | Incyte Corp | {1-{1-[3-flúor-2-(trifluormetil)isonicotinol]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]primidin-4-il) -1h-pirazol-1-il]azetidin-3-il}acetonitrila, seu uso, formas de dosagem de liberação sustentada e doses |
US10329288B2 (en) * | 2013-08-22 | 2019-06-25 | Genentech, Inc. | Process for preparing a compound |
WO2015027090A1 (en) * | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Intermediates and processes for preparing compounds |
CN106061973B (zh) | 2013-12-05 | 2019-07-09 | 辉瑞公司 | 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺 |
WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
ES2842592T3 (es) | 2014-05-19 | 2021-07-14 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 |
KR101710127B1 (ko) * | 2014-08-29 | 2017-02-27 | 한화제약주식회사 | 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민 |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
EP3216790B1 (en) * | 2014-11-05 | 2019-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof |
HUE064003T2 (hu) * | 2015-01-20 | 2024-02-28 | Wuxi Fortune Pharmaceutical Co Ltd | JAK-gátló |
CA2984183C (en) | 2015-05-01 | 2021-11-09 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
US10045981B2 (en) | 2015-11-24 | 2018-08-14 | Jakpharm, Llc | Selective kinase inhibitors |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
SG11201900515PA (en) | 2016-07-21 | 2019-02-27 | Biogen Ma Inc | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
CN106120090A (zh) * | 2016-08-31 | 2016-11-16 | 飞佛特种纺织品(宁波)有限公司 | 一种防刮擦阳光面料的制备方法 |
MX2019005319A (es) | 2016-11-23 | 2019-06-20 | Jiangsu Hengrui Medicine Co | Método de preparación e intermediario de derivado de un anillo heteroaromático de seis miembros pirrolo. |
JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
CN107337676A (zh) * | 2017-06-08 | 2017-11-10 | 江苏正大清江制药有限公司 | 一种托法替布起始原料的制备方法 |
FI3645001T3 (fi) | 2017-06-29 | 2024-09-25 | G1 Therapeutics Inc | Git38:n morfisia muotoja ja niiden valmistusmenetelmiä |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
WO2020041770A1 (en) | 2018-08-24 | 2020-02-27 | G1 Therapeutics, Inc. | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US11738026B2 (en) | 2019-11-22 | 2023-08-29 | Incyte Corporation | Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN114591321A (zh) * | 2020-12-04 | 2022-06-07 | 广州费米子科技有限责任公司 | 氮杂并环化合物、其制备方法及其用途 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3670079A (en) * | 1970-10-06 | 1972-06-13 | Merck & Co Inc | Anabolic agents |
US4997936A (en) * | 1977-10-19 | 1991-03-05 | Merck & Co., Inc. | 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids |
US4456464A (en) * | 1982-05-19 | 1984-06-26 | Zoecon Corporation | Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control |
US4526608A (en) * | 1982-07-14 | 1985-07-02 | Zoecon Corporation | Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use |
US4590282A (en) * | 1984-09-24 | 1986-05-20 | Sandoz Ltd. | Pest control agents |
US4933339A (en) * | 1985-08-21 | 1990-06-12 | Rohm And Haas Company | (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity |
CA1328333C (en) * | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
US4879309A (en) * | 1988-09-27 | 1989-11-07 | Schering Corporation | Mercapto-acylamino acids as antihypertensives |
US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
EP0682027B1 (de) | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
DE69531558T2 (de) | 1995-06-07 | 2004-03-18 | Pfizer Inc. | Heterocyclische kondensierte pyrimidin-derivate |
EP0836602B1 (en) | 1995-07-05 | 2002-01-30 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
CN1168138A (zh) | 1995-11-14 | 1997-12-17 | 法玛西雅厄普约翰公司 | 芳基和杂芳基嘌呤化合物 |
DE69712745T2 (de) | 1996-01-23 | 2002-10-31 | Novartis Ag, Basel | Pyrrolopyrimidinen und verfahren zu deren herstellung |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69718472T2 (de) | 1996-07-13 | 2003-11-06 | Glaxo Group Ltd., Greenford | Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren |
DK0938486T3 (da) | 1996-08-23 | 2008-07-07 | Novartis Ag | Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
AU4718997A (en) | 1996-11-27 | 1998-06-22 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
US6187552B1 (en) | 1997-03-24 | 2001-02-13 | Pharmacia & Upjohn Company | Method for identifying inhibitors of JAK2/cytokine receptor binding |
AU3378799A (en) | 1998-04-02 | 1999-10-25 | Neurogen Corporation | Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors |
CA2333392A1 (en) | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
RS50087B (sr) * | 1998-06-19 | 2009-01-22 | Pfizer Products Inc., | Pirolo (2,3-d) pirimidin jedinjenja |
JP2004504259A (ja) | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Jak−3インヒビターを用いたc−jun発現の阻害方法 |
MXPA01001893A (es) | 1998-08-21 | 2002-04-24 | Parker Hughes Inst | Derivados de quinazolina. |
PL346700A1 (en) * | 1998-09-18 | 2002-02-25 | Basf Ag | Pyrrolopyrimidines as protein kinase inhibitors |
CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
ES2258476T3 (es) * | 1999-09-30 | 2006-09-01 | Neurogen Corporation | Ciertos heterociclos sustituidos con alquilendiaminas. |
PT1235830E (pt) * | 1999-12-10 | 2004-04-30 | Pfizer Prod Inc | Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases |
US7301023B2 (en) * | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7253166B2 (en) * | 2003-04-22 | 2007-08-07 | Irm Llc | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells |
TW200615268A (en) * | 2004-08-02 | 2006-05-16 | Osi Pharm Inc | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
-
2001
- 2001-06-05 SI SI200130528T patent/SI1294724T1/sl unknown
- 2001-06-05 KR KR10-2002-7017610A patent/KR100516419B1/ko not_active IP Right Cessation
- 2001-06-05 CZ CZ20023993A patent/CZ20023993A3/cs unknown
- 2001-06-05 EA EA200201096A patent/EA006153B1/ru not_active IP Right Cessation
- 2001-06-05 AT AT01934243T patent/ATE323704T1/de not_active IP Right Cessation
- 2001-06-05 OA OA1200200385A patent/OA12292A/en unknown
- 2001-06-05 DE DE60137734T patent/DE60137734D1/de not_active Expired - Lifetime
- 2001-06-05 PT PT01934243T patent/PT1294724E/pt unknown
- 2001-06-05 AT AT06007969T patent/ATE423120T1/de not_active IP Right Cessation
- 2001-06-05 DK DK01934243T patent/DK1294724T3/da active
- 2001-06-05 PL PL01359563A patent/PL359563A1/xx not_active Application Discontinuation
- 2001-06-05 AP APAP/P/2002/002695A patent/AP1911A/en active
- 2001-06-05 DE DE60118917T patent/DE60118917T2/de not_active Expired - Lifetime
- 2001-06-05 SK SK1734-2002A patent/SK17342002A3/sk unknown
- 2001-06-05 GE GE5008A patent/GEP20053541B/en unknown
- 2001-06-05 BR BR0111561-8A patent/BR0111561A/pt not_active IP Right Cessation
- 2001-06-05 EP EP06007969A patent/EP1686130B1/en not_active Expired - Lifetime
- 2001-06-05 CA CA002412560A patent/CA2412560C/en not_active Expired - Fee Related
- 2001-06-05 AU AU60538/01A patent/AU784297C/en not_active Ceased
- 2001-06-05 CN CNB018117929A patent/CN100351253C/zh not_active Expired - Fee Related
- 2001-06-05 HU HU0301114A patent/HUP0301114A3/hu unknown
- 2001-06-05 WO PCT/IB2001/000975 patent/WO2002000661A1/en active IP Right Grant
- 2001-06-05 YU YU83302A patent/YU83302A/sh unknown
- 2001-06-05 NZ NZ522364A patent/NZ522364A/en unknown
- 2001-06-05 DK DK06007969T patent/DK1686130T3/da active
- 2001-06-05 DZ DZ013359A patent/DZ3359A1/fr active
- 2001-06-05 UA UA2002118861A patent/UA74370C2/uk unknown
- 2001-06-05 JP JP2002505785A patent/JP4068958B2/ja not_active Expired - Fee Related
- 2001-06-05 ES ES06007969T patent/ES2318605T3/es not_active Expired - Lifetime
- 2001-06-05 ES ES01934243T patent/ES2257410T3/es not_active Expired - Lifetime
- 2001-06-05 EE EEP200200711A patent/EE200200711A/xx unknown
- 2001-06-05 EP EP01934243A patent/EP1294724B1/en not_active Expired - Lifetime
- 2001-06-05 IL IL15277101A patent/IL152771A0/xx unknown
- 2001-06-05 MX MXPA03000068A patent/MXPA03000068A/es active IP Right Grant
- 2001-06-20 TW TW090115016A patent/TWI243820B/zh not_active IP Right Cessation
- 2001-06-21 GT GT200100117A patent/GT200100117A/es unknown
- 2001-06-25 TN TNTNSN01095A patent/TNSN01095A1/fr unknown
- 2001-06-25 SV SV2001000506A patent/SV2002000506A/es not_active Application Discontinuation
- 2001-06-25 AR ARP010103013A patent/AR029279A1/es active IP Right Grant
- 2001-06-25 PE PE2001000614A patent/PE20020381A1/es not_active Application Discontinuation
- 2001-06-25 US US09/891,028 patent/US6696567B2/en not_active Expired - Fee Related
- 2001-06-25 MY MYPI20012986 patent/MY127236A/en unknown
- 2001-06-26 DO DO2001000200A patent/DOP2001000200A/es unknown
- 2001-06-26 EC EC2001004105A patent/ECSP014105A/es unknown
- 2001-06-26 PA PA20018521101A patent/PA8521101A1/es unknown
-
2002
- 2002-10-31 IS IS6606A patent/IS2305B/is unknown
- 2002-10-31 BG BG107236A patent/BG107236A/bg unknown
- 2002-11-11 IL IL152771A patent/IL152771A/en not_active IP Right Cessation
- 2002-11-27 CU CU20020290A patent/CU23263B7/es not_active IP Right Cessation
- 2002-12-12 HR HR20021000A patent/HRP20021000A2/hr not_active Application Discontinuation
- 2002-12-16 NO NO20026030A patent/NO324934B1/no not_active IP Right Cessation
- 2002-12-19 ZA ZA200210275A patent/ZA200210275B/en unknown
- 2002-12-20 MA MA26969A patent/MA26917A1/fr unknown
-
2003
- 2003-06-16 US US10/463,724 patent/US6962993B2/en not_active Expired - Fee Related
- 2003-10-03 HK HK03107143A patent/HK1054930A1/xx not_active IP Right Cessation
-
2005
- 2005-04-21 US US11/112,307 patent/US7192963B2/en not_active Expired - Fee Related
-
2007
- 2007-02-22 US US11/710,164 patent/US20070161666A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO324934B1 (no) | Pyrrolo[2,3-d]pyramidinforbindelser som immunosuppresive midler | |
AP1157A (en) | Pyrrolo {2,3-d} pyrimidine compounds. | |
AU777911B2 (en) | Pyrrolo(2,3-d)pyrimidine compounds | |
CA3159188A1 (en) | Pyridazinones as parp7 inhibitors | |
EP3512857B1 (en) | Spiro bicyclic inhibitors of menin-mll interaction | |
MXPA06005882A (es) | Metodo de tratamiento de la aterosclerosis. | |
CA2782684A1 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
TW200418482A (en) | Method of treatment of transplant rejection | |
SK14652003A3 (sk) | Spôsob optického rozlíšenia (1-benzyl-4-metylpiperidín-3-yl)- metylamínu a jeho použitie a prípravu derivátov pyrol[2,3-d]pyrimidínu, a ich použitie ako inhibítorov proteínkináz | |
EP1734967A2 (en) | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |